Research Article

Network Pharmacology Study on Molecular Mechanisms of Zhishi Xiebai Guizhi Decoction in the Treatment of Coronary Heart Disease

Jin Gao 1, Yujing Pan 2, Yuxi Zhao 3, Haoyang Li 4, Zishuo Mi 5, Hao Chen 2 and Xiaodong Tan 6

1 School of Integrated Chinese and Western Medicine, Nanjing 210023, China
2 School of Acupuncture and Massage, Nanjing University of Chinese Medicine, Nanjing 210023, China
3 College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China
4 First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China
5 School of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China
6 Department of Cardiovascular Medicine, Hospital of Traditional Chinese Medicine of Wuxi City, Wuxi 214000, China

Correspondence should be addressed to Hao Chen; chenhao@njucm.edu.cn and Xiaodong Tan; txd198523@163.com

Received 5 August 2021; Revised 15 October 2021; Accepted 25 November 2021; Published 20 December 2021

Academic Editor: Vahidreza Ostadmohammadi

Copyright © 2021 Jin Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Coronary heart disease is characterized by the formation of arterial plaque. If not taken seriously, it will cause serious consequences such as myocardial infarction and heart failure. Zhishi Xiebai Guizhi Decoction first appeared in “Synopsis of Prescriptions of the Golden Chamber” and is a representative prescription for the treatment of coronary heart disease. This study aims to explain the mechanism of Zhishi Xiebai Guizhi Decoction in the treatment of coronary heart disease through network pharmacology and clinical trials.

Methods. We first identified the core compounds of Zhishi Xiebai Guizhi Decoction and their potential targets through TCMSP. Then, we analyzed the molecular targets of Zhishi Xiebai Guizhi Decoction in coronary heart disease with OMIM and GeneCards databases. After the common targets were screened out, we manage to figure out the pathways of these target genes through STRING. Finally, we verify the treatment results in clinical trials.

Results. Through network pharmacology analysis, we discovered that several core compounds of Zhishi Xiebai Guizhi Decoction have anti-inflammatory effects and are of great significance to treatment of cardiovascular diseases. The mechanism may be closely related to PPARγ, inflammation, TNF signaling pathway, AMPK signaling pathway, and PI3K-Akt signaling pathway. Clinical trials have also proved the key role of inflammation.

Conclusions. Zhishi Xiebai Guizhi Decoction may play a role in treating coronary heart disease by activating PPARγ. TNF signaling pathway, AMPK signaling pathway, and PI3K-Akt signaling pathway are potential mechanisms as well. The application of network pharmacology can provide a novel method for the research of Chinese herbal medicine. We hope that Zhishi Xiebai Guizhi Decoction will be recognized as a complementary or alternative treatment for coronary heart disease.

1. Introduction

Coronary heart disease (CHD) is characterized by formation of arterial plaques which are mainly comprised of lipids, calcium, and inflammatory cells [1]. These plaques narrow the lumen of coronary arteries leading to episodic or persistent angina. Rupture of these plaques results in the appearance of thrombus, which, brought about by cessation of blood flow, causes myocardial infarct and death [2]. CHD is one of the leading causes of death worldwide [3, 4]. The increasing number of CHD patients will lay a heavy economic burden on society [5]. Currently, the drugs commonly used in clinic to treat coronary heart disease are statins, nitrate esters, etc., with which the residual risk of cardiovascular events cannot be completely eliminated after treatment [6, 7]. Given this, many doctors have been seeking...
alternative medicines to treat CHD. Traditional Chinese medicine (TCM), as a type of alternative drug, displays the merits of low side effects and less irritation to the gastrointestinal tract [8, 9]. It has been demonstrated that TCM works an outstanding clinical effect when treating CHD [10]. Zhishi Xiebai Guizhi Decoction is effective. This prescription contains Aurantii Fructus Immaturus ("ZhiShi" in Chinese, ZS), Allium Azureum Ledeb. ("XieBai" in Chinese, XB), Cinnamomi Ramulus ("GuiZhi" in Chinese, GZ), Trichosanthes Kirilowii Maxim ("GuaLou" in Chinese, GL), and Magnolia Officinalis Rehd Et Wils. ("HouPo" in Chinese, HP). Multidrug compatibility is regarded as the essence of TCM theory [11]. However, due to the complex components and numerous targets involved, fully elucidating its mechanism using traditional methods is challenging. Therefore, it is necessary to reveal the potential mechanism of Zhishi Xiebai Guizhi Decoction in the treatment of CHD at the systemic level.

With the continuous innovation and development of systems biology and computer technology, the network pharmacology has been confirmed as a feasible choice to explicate the substance composition and molecular mechanism of TCM effectively and systemically [12, 13]. In 2008, Hopkins proposed the concept of network pharmacology [14]. Because network pharmacology can provide a full or partial understanding of the principles of network theory and systems biology, it has been considered the next paradigm in drug discovery. In addition, the network pharmacology approach has been used to study “compound-proteins/genes-disease” pathways, which are capable of describing complexities among biological systems, drugs, and diseases from a network perspective, sharing a similar holistic philosophy as TCM [15]. The application of systems biology methods to study the pharmacological effects, mechanism of action, and safety of TCM is of great significance to modern research and development of TCM. Thus, a new interdisciplinary method termed TCM network pharmacology has been proposed, which has initiated a new research paradigm for transforming TCM from an experience-based to evidence-based medicine. Furthermore, with recent advances in molecular biology and genomic technologies, an increasing amount of data has become available [16], for example, TCMSP [17], STRING [18], OMIM [19], and DisGeNET [20].

In this study, we used network pharmacology to predict the potential mechanism of Zhishi Xiebai Guizhi Decoction in the treatment of CHD. The workflow is displayed in Figure 1.

2. Methods

2.1. Screening the Chemical Components of Zhishi Xiebai Guizhi Decoction and Predicting the Component-Targets. The chemical ingredients of Zhishi Xiebai Guizhi Decoction were screened from TCMSP (http://lsp.nwu.edu.cn/tcmsp.php). Based on a previously reported model, we screened the various compounds in Zhishi Xiebai Guizhi Decoction according to their pharmacokinetic absorption, distribution, metabolism, and excretion, which is known as ADME process. TCMSP database details the ADME parameters of each component, including oral bioavailability (OB), druglikeness (DL), and blood-brain barrier (BBB). Ingredients meeting the demands of both OB ≥ 30% and DL ≥ 0.18 were selected to find the effective components of this prescription [21]. OB represents the oral availability of pharmaceutical ingredients, and DL refers to the similarity between a component and a known drug. Subsequently, the components in the prescription were selected (Table 1).

2.2. Predicting the Target Proteins of the Selected Compounds. All the active ingredients were input into the TCMSP database to obtain their known targets, and the Cytoscape3.8.2 tool was used to draw a network diagram of the compound and the target protein (Figure 2).

The blue nodes represent Zhishi, Xiebai, Guizhi, Gualou, and Houpo. The red nodes represent the compounds shared by Guizhi and Xiebai. The dark purple nodes represent the compounds of Houpo. The orange nodes represent the compounds of Zhishi. The light purple nodes represent the compounds of Xiebai. The pink nodes represent the compounds of Gualou. The yellow nodes represent the compounds of Guizhi. The green nodes represent the targets related to Zhishi Xiebai Guizhi Decoction.

2.3. Seeking Out Disease-Related Targets. With “coronary heart disease” as the keywords, OMIM (https://www.omim.org/) and GeneCards (https://www.genecards.org/) were used to search and screen the known disease-targets for the subsequent study, and the repeated targets in the search results were discarded. UniProt knowledge base [22, 23] (https://www.uniprot.org/) was used to get the standard targets’ names with the organism selected as “Homo sapiens.”

2.4. Searching for Common Targets and Key Targets of Zhishi Xiebai Guizhi Decoction and CHD. The common targets of drug and disease were found, and a Venn diagram was drawn (Figure 3).

The obtained intersection target was used as the drug effect target, and Cytoscape3.8.2 was employed to construct the drug effect target-component interaction network (Figure 4). The network was analyzed to get its degree value and get the key drug effect target (Table 2).

The green nodes represent the compounds of Zhishi Xiebai Guizhi Decoction. The blue nodes represent the key targets related to Zhishi Xiebai Guizhi Decoction.

2.5. Construction of the Protein-Protein Interaction Network. Using the STRING (Search Tool for the Retrieval of Interacting Gene/Proteins) database containing known and predicted PPIs [24], we constructed a protein-protein interaction (PPI) network of potential target genes of Zhishi Xiebai Guizhi Decoction in CHD (Figure 5).
2.6. Enrichment Analysis. To identify the biological process and signaling pathways in which the main hub target genes are involved, Database for Annotation, Visualization, and Integrated Discovery (David) were used for pathway enrichment analysis. The target genes of Zhishi Xiebai Guizhi Decoction in CHD were input into David for Gene Ontology (GO) biological process analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. GO biological processes with \( P \leq 0.01 \) and KEGG pathways with \( P \leq 0.01 \) were considered to be significantly enriched.

2.7. Clinical Index Changes of Zhishi Xiebai Guizhi Decoction in Treating Coronary Heart Disease Patients. A total of 176 patients with coronary heart disease were included in the clinical study. According to the random number table, the enrolled patients were divided into control group (88 cases) and the test group (88 cases). During the treatment, 7 cases were dropped from the two groups, and final effective cases were 81 cases in each group. This study was approved by the Ethics Committee of Wuxi Hospital of Traditional Chinese Medicine and registered in the Chinese Clinical Trial Registration Center (ethics number: 2018022736, registration number: ChiCTR1800019814). Before entering the group, patients and their family members were informed of all the research content and interests, were fully aware of them, and signed an informed consent form on the premise of voluntary participation. The diagnostic criteria for patients with coronary heart disease enrolled in this trial were based on the “2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology [25],” and the most diagnosed patients were patients with stable coronary artery disease. After admission, both groups were given standardized treatment for stable coronary heart disease. The test group was treated with Zhishi Xiebai Guizhi Decoction on the basis of the control group. Both groups were treated for 2 months and finally got inflammations such as Neutrophil to lymphocyte ratio (NLR), Monocyte of lymphocyte ratio (MLR), Monocyte to high-density lipoprotein ratio (MHR), and C-reactive protein (CRP) factor level changes, and preliminary exploration of the mechanism of the prescription on the inflammatory response provided a clinical basis for the later confirmation of its molecular mechanism in vitro and in vivo.

3. Results

3.1. Identification of Targets of Zhishi Xiebai Guizhi Decoction and CHD in Various Databases. The database retrieved 139 relevant targets of the active ingredient, and the active ingredient-target interaction network was constructed using Cytoscape 3.8.2 (Figure 2). Through keyword search, 1991 related targets of coronary heart disease were obtained in GeneCards database and OMIM database. The Venny diagram constructs the intersection of active ingredient-target and disease-target. A total of 85 intersection targets are used for subsequent network pharmacological analysis.

3.2. Seeking Key Targets and Built PPI Networks. The obtained intersection target was used as the drug effect target, and Cytoscape 3.8.2 was used to construct the drug effect target-component interaction network (Figure 4). The network was analyzed to get its degree value. The top 20 pharmacodynamic targets with degree value include estrogen receptor (ESR1), androgen receptor (AR), prostaglandin G/H synthase 2 (PTGS2), and peroxisome proliferator activated receptor (PPARG) (Table 2).

3.3. Enrichment Analysis by GO and KEGG. According to \( P \) value, the important items of BP of GO analysis were regulation of blood pressure, regulation of inflammatory...
response, blood circulation, cellular response to lipid, cellular response to peptide, response to hormone, negative regulation of apoptotic process, regulation of immune response, regulation of acute inflammatory response, regulation of cytokine production involved in inflammatory response, and positive regulation of acute inflammatory response (Figure 6). The results showed that Zhishi Xiebai Guizhi Decoction is closely related to inflammatory reaction in the treatment of CHD.

According to the $P$ value, a total of 29 pathways were screened by KEGG analysis, including pathways in cancer, adrenergic signaling in cardiomyocytes, IL-17 signaling

| Drug ID     | Components                                  | OB%   | DL  |
|------------|---------------------------------------------|-------|-----|
| MOL001494  | Mandenol                                    | 41.9962 | 0.19321 |
| MOL002881  | Diosmetin                                   | 31.13795 | 0.27442 |
| MOL004355  | Spinasterol                                  | 42.97937 | 0.75534 |
| MOL005530  | Hydroxykwanin                               | 36.467 | 0.27206 |
| MOL006756  | Schottenol                                   | 37.42312 | 0.75067 |
| MOL007165  | 10α-cucubita-5,24-diene-3β-ol               | 44.01594 | 0.7445 |
| MOL007171  | 5-Dehydrokarounidol                         | 30.22665 | 0.7703 |
| MOL007172  | 7-Oxo-dihydrokaruo-nidol                    | 36.85021 | 0.75387 |
| MOL007175  | Karounidol 3-o-benzoate                     | 43.99061 | 0.49505 |
| MOL007179  | Linolenic acid ethyl ester                  | 46.10096 | 0.19694 |
| MOL007180  | Vitamin-e                                   | 32.28643 | 0.69563 |
| HP         | Eucalyptol                                  | 60.62476 | 0.32159 |
| MOL009580  | Neohesperidin                               | 57.44074 | 0.27085 |
| GZ         | Ent-epicatechin                             | 48.95984 | 0.24162 |
| MOL000358  | Beta-sitosterol                             | 36.91391 | 0.75123 |
| MOL000359  | Sitosterol                                  | 36.91391 | 0.7512 |
| MOL000492  | (+)-catechin                                | 54.82643 | 0.24164 |
| MOL001736  | (−)-Taxifolin                               | 60.50622 | 0.27342 |
| MOL000998  | Quercetin                                   | 46.43335 | 0.27525 |
| MOL000332  | n-coumarolyltrimepane                       | 85.62883 | 0.20287 |
| MOL003358  | Beta-sitosterol                             | 36.91391 | 0.75123 |
| MOL004843  | (Z)-3-(4-Hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl) ethyl] acrylamide | 118.3477 | 0.26399 |
| MOL006631  | Coumaroylamine                              | 112.9016 | 0.20234 |
| XB         | Sitosterol acetate                          | 40.38964 | 0.85102 |
| MOL002341  | Hesperetin                                  | 70.31209 | 0.27252 |
| MOL004328  | Naringenin                                  | 59.2939 | 0.21128 |
| MOL007640  | Macrostemonoside e_qt                       | 35.259 | 0.87216 |
| MOL007650  | PGA (sup 1)                                 | 43.98251 | 0.25437 |
| MOL007651  | Prostaglandin B1                            | 40.20777 | 0.25384 |
| MOL000006  | Luteolin                                    | 36.16263 | 0.24552 |
| MOL001798  | Neohesperidin_qt                            | 71.16886 | 0.27085 |
| MOL00803   | Sinenestin                                  | 50.55685 | 0.44634 |
| MOL00914   | Ammidin                                     | 34.58456 | 0.22355 |
| MOL002914  | Eriodictiol (flavonone)                     | 41.35043 | 0.2436 |
| MOL004328  | Naringenin                                  | 59.2939 | 0.21128 |
| MOL005100  | 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl) chroman-4-one | 47.73644 | 0.27226 |
| MOL005828  | Nobiletin                                   | 61.66944 | 0.51652 |
| MOL005849  | Didymin                                     | 38.55139 | 0.23908 |
| MOL007879  | Tetramethoxyluteolin                        | 43.68476 | 0.37009 |
| ZS         | 4-[(2S,3R)-5-[(E)-3-Hydroxyprop-1-enyl]-7-methoxy-3-methylol-2,3-dihydrobenzofuran-2-yl]-2-methoxy-phenol | 50.75514 | 0.3948 |
| MOL013276  | Poncirin                                    | 36.54601 | 0.74202 |
| MOL013277  | Isosinensetin                               | 51.15169 | 0.44149 |
| MOL013279  | 5,7,4′-Trimethylapigenin                    | 39.83272 | 0.29366 |
| MOL013352  | Obacunone                                   | 43.28625 | 0.76724 |
| MOL013428  | Isosakuranetin-7-rutinoside                 | 41.24037 | 0.71616 |
| MOL013430  | Prangenin                                   | 43.59734 | 0.29428 |
| MOL013433  | Prangenin hydrate                           | 72.63401 | 0.28863 |
| MOL013435  | Poncimararin                                | 63.62093 | 0.34942 |
| MOL013436  | Isoponcimararin                             | 63.2776 | 0.31316 |
| MOL013437  | 6-Methoxy aurapten                          | 31.23777 | 0.3008 |
| MOL013440  | Citrusin B                                  | 40.79717 | 0.71331 |
3.4. Clinical Trial Results. The CRP of the two groups of patients before and after treatment showed a skewed distribution, so the median (interquartile range) was used to describe the difference, and nonparametric tests were used to compare the differences (Figure 8). The comparison of CRP in the two groups before and after treatment was statistically significant ($P < 0.05$), and the CRP levels in both the test group and the control group decreased after treatment. After rank sum test, there was no statistically significant difference between the two groups before treatment ($P > 0.05$), and there was no significant difference in CRP between the two groups after treatment ($P > 0.05$) (Table 3).

\[ \text{Teseb} = \text{before treatment in the test group; Testa} = \text{after treatment in the test group} \]
\[ \text{Controlb} = \text{before treatment in the control group; Controla} = \text{after treatment in the control group} \]

The NLR of the two groups of patients before and after treatment showed a skewed distribution, so the median (interquartile range) was used to describe the difference, and the difference was compared with nonparametric tests (Table 4). The comparison of NLR in the two groups before and after treatment was statistically significant ($P < 0.05$), and the NLR levels in both the test group and the control
group decreased after treatment. After the rank sum test, there was no statistical difference between the two groups before treatment ($P > 0.05$), and the difference in NLR between the two groups after treatment was statistically significant ($P < 0.05$).

The MLR of the two groups of patients before and after treatment showed a skewed distribution, so the median (interquartile range) was used to describe the difference, and the difference was compared with nonparametric tests (Table 5). The comparison of MHR in the two groups before and after treatment was statistically significant ($P < 0.05$), and the MHR levels in both the test group and the control group decreased after treatment. After the rank sum test, there was no statistical difference between the two groups before treatment ($P > 0.05$), and the difference in MHR between the two groups after treatment was statistically significant ($P < 0.05$).

4. Discussion

4.1. Summary of Findings. Coronary heart disease is a common cardiovascular disease, caused by coronary atherosclerosis. If not taken seriously, it will cause serious consequences such as myocardial infarction and heart failure [26]. In our study, Zhishi Xiebai Guizhi Decoction was used to treat coronary heart disease. However, illuminating the complex mechanisms of Zhishi Xiebai Guizhi Decoction in the treatment of CHD using traditional methods is challenging. Therefore, the integration of network pharmacology is essential sense based on big data bioinformatics into the study of the molecular mechanisms of TCM in the treatment of diseases [27, 28]. In the present study, network pharmacology was used to explore the material basis and molecular mechanism of Zhishi Xiebai Guizhi Decoction for treatment of CHD.

From the network of herbs, natural compounds, and targets, we found the core compounds of this prescription were quercetin, naringenin, luteolin, (+)-catechin, hesperetin, etc. Quercetin, a flavonoid, is one of the polyphenols characterized as the compounds containing large multiples of phenol structural units [29]. It can reduce blood pressure and promote angiogenesis through anti-inflammatory, antioxidant, immune, and other ways [30]. It is a potential protector of coronary heart disease.
cancers, and inflammatory bowel disease [31]. It exhibits significant heart related benefits as inhibition of LDL oxidation, endothelium-independent vasodilator effects, and other inflammatory effects [32]. Naringenin has the functions of lowering lipid, anti-inflammatory, anti-allergic, antithrombotic effects, and promoting atherosclerosis regression [33–35]. Luteolin administration improved cardiac function, attenuated the inflammatory response, alleviated mitochondrial injury, decreased oxidative stress, inhibited cardiac apoptosis, and enhanced autophagy [36, 37]. Studies have shown that it can attenuate isoproterenol-induced myocardial injury and fibrosis in mice [38].

85 common targets were found for drugs and diseases, which might be targets for this prescription when treating CHD. Based on the topological analysis, we further found the 20 critical targets from the 85 common targets for subsequent study, including estrogen receptor (ESR1), androgen receptor (AR), prostaglandin G/H synthase 2 (PTGS2), and peroxisome proliferator activated receptor gamma (PPARG). A number of studies also provide evidence for an inhibitory role of PPARγ in atherosclerosis and that it may exert atheroprotective effects [39]. The human PPARγ gene is located on chromosome 3 at position 3p25 and gives rise to three different mRNAs isoforms, γ1, γ2, and γ3. Among them, PPARγ3 is predominantly expressed in macrophages, the large intestine, and adipose tissue [40]. The pleiotropic effects of PPARs show the potential of this drug class in terms of treating atherosclerotic disease in the future [41–43], including their ability to decrease thrombosis, cell recruitment, cell activation, foam cell formation, and inflammatory responses, and their concurrent ability to improve plaque stability, endothelial function, endothelial progenitor cell biology, and C efflux. In human atherosclerotic lesions, PPARγ activation has been reported to promote differentiation of proatherogenic M1 macrophages into an alternative anti-inflammatory phenotype, M2, which could protect against the development of atherosclerosis. There is accumulating evidence suggesting that activated PPAR has powerful antiatherosclerotic properties, which not only directly afects the blood vessel wall but also indirectly affects systemic inflammation [42]. A combination of our GO analysis, clinical trials, and other modern studies has confirmed the important role of inflammation in CHD. KEGG enrichment analysis shows the important position of AMPK, TNF, and PI3K-Akt signaling pathway in CHD [44–46]. PPARγ plays a vital role in these pathways.
4.2. Implication for Clinical Trial. As we all know, inflammatory is of great essence in the pathogenesis of CHD [2]. Among the various inflammatory factors, besides the CRP that has been widely used in clinical practice, it has been generally recognized. In addition, clinical studies have confirmed that white blood cells and their subtypes are closely related to cardiovascular disease caused by atherosclerosis [47]. White blood cells are an important marker of inflammation. In recent years, experts have integrated various subtypes and recently proposed three indicators: Monocyte to lymphocyte ratio (MLR), Neutrophil to lymphocyte ratio (NLR), and Monocyte to high-density lipoprotein ratio (MHR) [48–52]. They can all be regarded as a kind of inflammatory markers and are related to coronary heart disease [53]. Almost all the compounds in Zhishi Xiebai Guizhi Decoction have anti-inflammatory effects, so we speculate that Zhishi Xiebai Guizhi Decoction treats CHD through inflammation.

4.3. Limitations. The key targets and/or pathways found in network pharmacology have not been verified in clinical trials, but NLR, NHR, and MHR can all be regarded as a kind of inflammatory markers and are related to coronary heart disease. The key targets and pathways also play an important role in inflammation. In the future, we need to verify our conjecture through animal experiments.

5. Conclusions

This study combined network pharmacology and clinical trials to explore the mechanism of Zhishi Xiebai Guizhi Decoction in the treatment of CHD. The results showed that Zhishi Xiebai Guizhi Decoction may exert antitherosclerosis effect through PPARy. In addition, TNF, AMPK, and PI3K-Akt signaling pathway may also be its potential mechanisms. We hope that computer biology can provide a method for the modern research of Chinese medicine, and Zhishi Xiebai Guizhi Decoction can be recognized as a complementary or alternative treatment for CHD.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.
Ethical Approval

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All human experiments were approved by the Ethics Committee of Wuxi Hospital of Traditional Chinese Medicine and registered in the Chinese Clinical Trial Registration Center (ethics number: 2018022736, registration number: ChiCTR1800019814).

Disclosure

J. Gao and Y.-J. Pan are the co-first authors.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

H. Chen contributed to conception and design and administrative support. X.-D. Tan contributed to the provision of study materials or patients. J. Gao and Y.-J. Pan contributed to the collection and assembly of data and data analysis and interpretation. All authors contributed to manuscript writing and final approval of the manuscript. All authors contributed equally to this work.

Acknowledgments

The authors sincerely thank Dr. Tiefeng Sun (Shandong Academy of Chinese Medicine) for his assistance in designing the study and experiments. The authors acknowledge Science and Education Strengthening Health Project of the Young Medical Talent Project of Wuxi Municipal Health Commission (QNRC085) and Scientific Research Project of Wuxi Municipal Health Commission (Q202045).

References

[1] G. Riccioni and V. Sbendorio, “Atherosclerosis: from biology to pharmacological treatment,” Journal of geriatric cardiology, vol. 9, no. 3, pp. 305–317, 2012.
[2] H. Li, K. Sun, R. Zhao et al., “Inflammatory biomarkers of coronary heart disease,” Frontiers in Bioscience, vol. 10, pp. 185–196, 2018.
[3] N. D. Wong, “Epidemiological studies of CHD and the evolution of preventive cardiology,” Nature Reviews Cardiology, vol. 11, no. 5, pp. 276–289, 2014.
[4] GBD 2013 Mortality and Causes of Death Collaborators, “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013,” Lancet (London, England), vol. 385, no. 9963, pp. 117–171, 2015.
[5] S. Negi and A. Anand, “Atherosclerotic coronary heart disease-epidemiology, classification and management,” Cardiovascular & Haematological Disorders-Drug Targets, vol. 10, no. 4, pp. 257–261, 2010.
[6] H. Agrawal, H. K. Choy, J. Liu, M. Auyoung, and M. A. Albert, “Coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 40, no. 7, pp. e185–e92, 2020.
[7] C.-Y. Wei, Y.-M. Wang, L. Han et al., “Nitrate esters alleviated coronary atherosclerosis through inhibition of NF-κB-Regulated macrophage polarization shift in epicardial adipose tissue,” Journal of Cardiovascular Pharmacology, vol. 75, no. 5, pp. 475–482, 2020.
[8] R. Chen, Y. Xiao, M. Chen et al., “A traditional Chinese medicine therapy for coronary heart disease after percutaneous coronary intervention: a meta-analysis of randomized, double-blind, placebo-controlled trials,” Bioscience Reports, vol. 38, no. 5, 2018.
[9] Y. Wang, X. Wang, J. Wang et al., “Tongmai Yangxin in intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial,” Trials, vol. 21, no. 1, p. 287, 2020.
[10] B. Liang, Y. Qu, Q.-F. Zhao, and N. Gu, “Guanyin V for coronary artery disease: a retrospective study,” Biomedicine & Pharmacotherapy, vol. 128, Article ID 110280, 2020.
[11] H. Shi, C. Dong, M. Wang et al., “Exploring the mechanism of Yizhi Tongmai decoction in the treatment of vascular dementia through network pharmacology and molecular docking,” Annals of Translational Medicine, vol. 9, no. 2, p. 164, 2021.
[12] T.-t. Luo, Y. Lu, S.-k. Yan, X. Xiao, X.-l. Rong, and J. Guo, “Network pharmacology in research of Chinese medicine formula: methodology, application and prospective,” Chinese Journal of Integrative Medicine, vol. 26, no. 1, pp. 72–80, 2020.
[13] S. Long, C. Yuan, Y. Wang, J. Zhang, and G. Li, “Network pharmacology analysis of damacanathicus indicus C.F.gaertn in gene-phenotype,” Evidence-based Complementary and Alternative Medicine, vol. 2019, Article ID 1368371, 2019.
[14] A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008.
[15] R. Zhang, X. Zhu, H. Bai, and K. Ning, “Network pharmacology databases for traditional Chinese medicine: review and assessment,” Frontiers in Pharmacology, vol. 10, p. 123, 2019.
[16] B. Boezio, K. Audouze, P. Ducrot, and O. Taboureau, “Network-based approaches in pharmacology,” Molecular Informatics, vol. 36, no. 10, 2017.
[17] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014.
[18] M. Kuhn, D. Szklarczyk, S. Pletschek-Frankild et al., “Stitch 4: integration of protein-chemical interactions with user data,” Nucleic Acids Research, vol. 42, no. Database issue, pp. D401–D407, 2014.
[19] J. S. Amberger, C. A. Bocchini, F. Schiettecatte, A. F. Scott, and A. Hamosh, “OMIM.org: online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders,” Nucleic Acids Research, vol. 43, no. Database issue, pp. D789–D798, 2015.
[20] J. Piñero, A Bravo, N. Queralt-Rosinach et al., “DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants,” Nucleic Acids Research, vol. 45, no. D1, pp. D833–D49, 2017.
[21] J. Li, Y. Huang, S. Zhao et al., “Based on network pharmacology to explore the molecular mechanisms of astragalus membranaceus for treating T2 diabetes mellitus,” Annals of Translational Medicine, vol. 7, no. 22, p. 633, 2019.
[22] UniProt Consortium, “UniProt: A worldwide hub of protein knowledge,” Nucleic Acids Research, vol. 47, no. D1, pp. D506–d15, 2019.
Evidence-Based Complementary and Alternative Medicine

10

[23] UniProt Consortium, "UniProt: The universal protein knowledgebase," Nucleic Acids Research, vol. 45, no. D1, pp. D158–D69, 2017.

[24] C. v. Mering, M. Huynen, D. J. Egg, S. Schmidt, P. Bork, and B. Snel, "STRING: a database of predicted functional associations between proteins," Nucleic Acids Research, vol. 31, no. 1, pp. 258–261, 2003.

[25] G. Montalvescot, U. Sechtem, S. Achenbach et al., "2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology," European Heart Journal, vol. 34, no. 38, pp. 2949–3003, 2013.

[26] K. D. Boudoulas, F. Tripiskiade, P. Geleser, and H. Boudoulas, "Coronary atherosclerosis: pathophysiologic basis for diagnosis and management," Progress in Cardiovascular Diseases, vol. 58, no. 6, pp. 676–692, 2016.

[27] S. Sheng, Z.-x. Yang, F.-q. Xu, and Y. Huang, "Network pharmacology-based exploration of synergistic mechanism of guaixin II formula (II) for coronary heart disease," Chinese Journal of Integrative Medicine, vol. 27, no. 2, pp. 106–114, 2021.

[28] J. Tai, J. Zou, X. Zhang et al., "Using network pharmacology to explore potential treatment mechanism for coronary heart disease using chuanxiong and jiangxiang essential oils in jingzhi guaixin prescriptions," Evidence-based Complementary and Alternative Medicine: eCAM, vol. 2019, Article ID 7631365, 2019.

[29] Y. Marunaka, R. Marunaka, H. Sun et al., "Actions of quercetin, a polyphenol, on blood pressure," Molecules, vol. 22, no. 2, 2017.

[30] Y. Li, J. Yao, C. Han et al., "Quercetin, inflammation and immunity," Nutrients, vol. 8, no. 3, p. 167, 2016.

[31] N. A. Al-Shabib, J. M. Khan, A. Malik et al., "A quercetin-based flavanoid (rutin) reverses amyloid fibrillation in β-lactoglobulin at pH 2.0 and 358 K," Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, vol. 214, pp. 40–48, 2019.

[32] R. V. Patel, B. M. Mistry, S. K. Shinde, R. Syed, V. Singh, and H.-S. Shin, "Therapeutic potential of quercetin as a cardiovascular agent," European Journal of Medicinal Chemistry, vol. 155, pp. 894–908, 2019.

[33] R. Joshi, Y. A. Kulkarni, and S. Wairkar, "Pharmacokinetic, pharmacodynamic and formulations aspects of Naringenin: an update," Life Sciences, vol. 215, pp. 43–56, 2018.

[34] A. C. Burke, B. G. Sutherland, D. E. Telford et al., "Naringenin enhances the regression of atherosclerosis induced by a chow diet in LDLr (-/-) mice," Atherosclerosis, vol. 286, pp. 60–70, 2019.

[35] W. Zeng, L. Jin, F. Zhang, C. Zhang, and W. Liang, "Naringenin as a potential immunomodulator in therapeutics," Pharmacological Research, vol. 135, pp. 122–126, 2018.

[36] N. Aziz, M.-Y. Kim, and J. Y. Cho, "Anti-inflammatory effects of luteolin: a review of in vitro, in vivo, and in silico studies," Journal of Ethnopharmacology, vol. 225, pp. 342–358, 2018.

[37] B. Wu, H. Song, M. Fan et al., "Luteolin attenuates sepsis-induced myocardial injury by enhancing autophagy in mice," International Journal of Molecular Medicine, vol. 45, no. 5, pp. 1477–1487, 2020.

[38] B.-b. Ning, Y. Zhang, D.-d. Wu et al., "Luteolin-7-diglucuronide attenuates isoproterenol-induced myocardial injury and fibrosis in mice," Acta Pharmacologica Sinica, vol. 38, no. 3, pp. 331–341, 2017.

[39] R. Marfella, M. D’Amico, K. Esposito et al., "The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment," Diabetes, vol. 55, no. 3, pp. 622–632, 2006.

[40] C. la Lastra, S. Sanchez-Fidalgo, I. Villegas, and V. Motilva, "New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists," Current Pharmaceutical Design, vol. 10, no. 26, pp. 3505–3524, 2004.

[41] L. Han, W.-J. Shen, S. Bittner, F. B. Kraemer, and S. Azhar, "PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ," Future Cardiology, vol. 13, no. 3, pp. 279–296, 2017.

[42] S. Verma and P. E. Szmitko, "The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis," Canadian Journal of Cardiology, vol. 22, no. Suppl B, pp. 12b–7b, 2006.

[43] S. S. Soskic, B. D. Dobutovic, E. M. Sudar et al., "Peroxisome proliferator-activated receptors and atherosclerosis," Angiology, vol. 62, no. 7, pp. 523–534, 2011.

[44] Y. Dong, H. Chen, J. Gao, Y. Liu, J. Li, and J. Wang, "Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease," Journal of Molecular and Cellular Cardiology, vol. 136, pp. 27–41, 2019.

[45] J. M. Li, W. Lu, J. Ye, Y. Han, H. Chen, and L. S. Wang, "Association between expression of AMPK pathway and adiponectin, leptin, and vascular endothelial function in rats with coronary heart disease," European Review for Medical and Pharmacological Sciences, vol. 24, no. 2, pp. 905–914, 2020.

[46] T. Chen, Y. Zhang, Y. Liu et al., "MiR-27a promotes insulin resistance and mediates glucose metabolism by targeting PPAR-γ-mediated PI3K/AKT signaling," Aging, vol. 11, no. 18, pp. 7510–7524, 2019.

[47] M. Madjid and O. Fatemi, "Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update," Texas Heart Institute Journal, vol. 40, no. 1, pp. 17–29, 2013.

[48] L. Wang, W. Long, P.-f. Li, Y.-b. Lin, and Y. Liang, "An elevated peripheral blood monocyte-to-lymphocyte ratio predicts poor prognosis in patients with primary pulmonary lymphoepithelioma-like carcinoma," PLoS One, vol. 10, no. 5, Article ID e0126269, 2015.

[49] M. E. Afari and T. Bhat, "Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update," Expert Review of Cardiovascular Therapy, vol. 14, no. 5, pp. 573–577, 2016.

[50] T. Bhat, S. Teli, J. Rijal et al., "Neutrophil to lymphocyte ratio and cardiovascular diseases: a review," Expert Review of Cardiovascular Therapy, vol. 11, no. 1, pp. 55–59, 2013.

[51] H. Kundi, E. Kiliztunc, M. Cetin et al., "Association of monocyte/HDL-C ratio with SYNTAX scores in patients with stable coronary artery disease," Herz, vol. 41, no. 6, pp. 523–529, 2016.

[52] P. Forget, C. Khalifa, J.-P. Defour, D. Latinne, M.-C. Van Pel, and M. De Kock, "What is the normal value of the neutrophil-to-lymphocyte ratio?" PLoS One, vol. 10, no. 12, p. 12, 2017.

[53] H. Chen, M. Li, L. Liu, X. Dang, D. Zhu, and G. Tian, "Monocyte/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients with non-ST-elevation myocardial infarction," Medicine, vol. 98, no. 26, Article ID e16267, 2019.